Bear's Head Tooth

Metadata

Regulatory Status

United States

• Dietary supplement: Available as a dietary supplement and gourmet food ingredient. Wild-harvested in eastern North American hardwood forests. Increasingly cultivated by specialty mushroom farms.
• FDA GRAS status: No specific GRAS determination for H. americanum. H. erinaceus has no GRAS determination either, though it has a long history of food use.
• Market note: Products are sometimes sold interchangeably with H. erinaceus under the name “Lion’s Mane.”

Canada

• Natural Health Products: Available as a natural health product ingredient. Wild-harvested across eastern Canada.

European Union

• Novel food: No specific authorization. H. erinaceus fruiting body has been consumed as food in the EU but concentrated extracts may require novel food authorization. H. americanum would likely face the same regulatory framework.
• Traditional use: No recognized tradition of medicinal use in European herbal medicine.

China and Japan

• China: H. erinaceus (Hou Tou Gu) is recognized in TCM. H. americanum is not specifically recognized in the Chinese Pharmacopoeia.
• Japan: H. erinaceus is cultivated and consumed widely. H. americanum is not specifically marketed or recognized.

Conditions & Indications

Primary: Neuroprotection and Cognitive Support (Preclinical Evidence, Extrapolated)

• NGF stimulation: Hericenones (found in fruiting bodies) and erinacines (found primarily in mycelium) from Hericium species stimulate the synthesis of nerve growth factor (NGF), which is critical for neuronal growth, maintenance, and repair. This mechanism has been thoroughly demonstrated for H. erinaceus and is believed to be shared by H. americanum based on shared compound chemistry.
• Neuroprotection: Ergothioneine, found in exceptionally high concentrations in H. americanum fruiting bodies, is a cytoprotective amino acid with antioxidant and anti-inflammatory properties specific to neural tissues. It is transported by OCTN1, which is highly expressed in the brain.
• Neurodegenerative disease potential: Extrapolated from H. erinaceus data, Hericium compounds may be beneficial for reducing cognitive decline and potentially alleviating symptoms of Alzheimer’s and Parkinson’s disease through NGF stimulation and reduction of neuroinflammation.

Secondary: Immune Modulation (Preclinical Evidence)

• Immunostimulation: H. americanum polysaccharides and beta-glucans have immunomodulatory properties, enhancing macrophage and NK cell activity. This is consistent with the broader Hericium genus and medicinal mushroom polysaccharide pharmacology.
• Anti-inflammatory: Polysaccharide and terpenoid fractions from Hericium species demonstrate anti-inflammatory activity through NF-kB pathway modulation.

Emerging/Preclinical

• Mood and anxiety: Extrapolated from H. erinaceus clinical data suggesting reduction in depression and anxiety scores. The shared NGF-stimulating chemistry provides a plausible mechanism.
• Gut-brain axis: H. erinaceus polysaccharides have demonstrated prebiotic effects that modulate gut microbiota composition, potentially influencing neurological function through the gut-brain axis. H. americanum polysaccharides may share these properties.
• Peripheral nerve regeneration: NGF-stimulating compounds from Hericium species have shown promise for peripheral nerve repair in preclinical models.

Mechanism of Action

Primary Mechanisms

1. Hericenone-mediated NGF synthesis: Hericenones C—H, aromatic meroterpenoids found in the fruiting body of Hericium species, stimulate NGF gene expression in astrocytes and other glial cells. NGF is essential for the survival, development, and function of cholinergic neurons in the basal forebrain, which are the neuronal population most affected in Alzheimer’s disease.

2. Erinacine-mediated NGF synthesis: Erinacines A, B, C, and S, cyathane diterpenoids found primarily in Hericium mycelium, are potent inducers of NGF synthesis. Erinacine A is the most studied and can cross the blood-brain barrier. These compounds stimulate NGF expression through activation of the JNK signaling pathway.

3. Ergothioneine neuroprotection: H. americanum fruiting bodies contain 376 mg ergothioneine per 100 g dry weight — among the highest concentrations reported in any mushroom species. Ergothioneine is a powerful antioxidant amino acid that accumulates in tissues with high oxidative stress (brain, liver, kidneys) via the specific transporter OCTN1. It protects neurons from oxidative damage, mitochondrial dysfunction, and excitotoxicity.

Secondary Mechanisms

• Beta-glucan immune activation: Polysaccharides with beta-1,3/1,6-glucan structures activate innate immune cells through dectin-1 and complement receptor 3 (CR3), promoting macrophage phagocytosis and cytokine release.
• Anti-neuroinflammatory activity: Terpenoid compounds from Hericium species suppress microglial activation and reduce production of pro-inflammatory mediators (iNOS, COX-2, TNF-alpha, IL-6) in brain tissue, potentially slowing neuroinflammation-driven neurodegeneration.
• Myelin regeneration support: Preclinical evidence from H. erinaceus suggests promotion of myelination processes, which may extend to H. americanum given the shared erinacine content.

Clinical Evidence Summary

No human clinical trials specifically evaluating H. americanum have been published. The evidence base for this species consists of analytical chemistry confirming shared bioactive compounds with H. erinaceus, and extrapolation from the H. erinaceus clinical literature.

Species-Specific Analytical Evidence

Key H. erinaceus Clinical Trials (Extrapolated Context)

Evidence Limitations

• No published clinical trials specific to H. americanum for any indication.
• Extrapolation from H. erinaceus data assumes comparable bioactive compound concentrations, which has not been rigorously quantified across all compound classes.
• The distribution of hericenones and erinacines may differ between H. americanum and H. erinaceus, potentially affecting relative potency for neurocognitive indications.
• Erinacines are primarily found in mycelium, while hericenones are in fruiting bodies. Products using different fungal parts may have very different pharmacological profiles.
• Commercial products labeled as “Lion’s Mane” may contain H. americanum, H. erinaceus, H. coralloides, or mixtures without species differentiation.

Safety Profile

General Assessment

H. americanum has a long history of safe consumption as an edible mushroom in North America. It is considered a choice edible species by foragers. No adverse events specific to H. americanum have been reported in the published literature. The safety profile is largely extrapolated from H. erinaceus, which has a good safety record in clinical trials and long history of food use in East Asia.

Contraindications

• Fungal allergy: Individuals with known allergies to Hericium species or other basidiomycete fungi should avoid use.
• Pregnancy and lactation: Insufficient safety data. No human studies in pregnant or lactating women. Avoid concentrated extracts.

Drug Interactions

• No established drug interactions specific to H. americanum or the broader Hericium genus have been reported in clinical literature. Theoretical considerations include:
  • Antidiabetic medications: H. erinaceus has demonstrated mild hypoglycemic effects in preclinical studies. Monitor blood glucose if combining.
  • Anticoagulants: Theoretical platelet aggregation inhibition has been reported for H. erinaceus polysaccharides in vitro, though clinical significance is uncertain.

Side Effects

• Common: Mild gastrointestinal discomfort (nausea, stomach upset) reported rarely with H. erinaceus preparations.
• Uncommon: Allergic skin reactions, particularly in individuals with pre-existing fungal sensitivities.
• Rare: Isolated case reports of allergic reactions with H. erinaceus; no adverse reaction reports specific to H. americanum.

Toxicology

No specific toxicological studies on H. americanum have been published. H. erinaceus has demonstrated no significant toxicity at doses up to 3 g/kg body weight in rodent acute toxicity studies. H. americanum is considered equally safe based on shared chemistry and extensive culinary use.

Clinical Dosage

Fresh Fruiting Body (Culinary)

• Dose: 100—300 g/day of fresh fruiting body, cooked
• Note: H. americanum is a prized edible mushroom. Cooking improves bioavailability of some compounds while potentially reducing others.

Dried Fruiting Body Powder

• Dose: 1—3 g/day of dried fruiting body powder
• Rationale: Extrapolated from H. erinaceus clinical trial dosing (typically 750—3,000 mg/day of dried fruiting body)

Hot-Water Extract

• Dose: Equivalent to 1—3 g dried fruiting body per day
• Note: Hot-water extraction captures polysaccharides (beta-glucans) and hericenones effectively

Dual Extract (Tincture)

• Dose: 2—4 mL/day of dual-extracted tincture
• Note: Alcohol extraction captures additional terpenoid compounds not soluble in water

Mycelium Extract

• Dose: 500—3,000 mg/day of mycelium biomass or extract
• Note: Mycelium is the primary source of erinacines, which are the most potent NGF stimulators. However, mycelium products grown on grain substrate may contain significant grain filler.

Form Selection Guidance

For neurocognitive indications, a combination of fruiting body (hericenones) and mycelium (erinacines) extracts provides the most complete bioactive profile. The high ergothioneine content of H. americanum fruiting bodies makes fruiting body preparations particularly valuable as a neuroprotective antioxidant source. Erinacine A, the most potent NGF inducer, is exclusively found in mycelium cultures.

Sources

• Thongbai B, Rapior S, Hyde KD, Wittstein K, Stadler M. Hericium erinaceus, an amazing medicinal mushroom. Mycol Prog. 2015;14:91
• Friedman M. Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (Lion’s Mane) mushroom fruiting bodies and mycelia and their bioactive compounds. J Agric Food Chem. 2015;63(32):7108-7123
• Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372
• Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231-237
• Li IC, Chang HH, Lin CH, Chen WP, Lu TH, Lee LY, et al. Prevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Front Aging Neurosci. 2020;12:155
• Roda E, Priori EC, Ratto D, De Luca F, Di Iorio C, Angelone P, et al. Neuroprotective metabolites of Hericium erinaceus promote neurohealth. Int J Mol Sci. 2021;22(12):6379
• Kalaras MD, Richie JP, Calcagnotto A, Beelman RB. Mushrooms: a rich source of the antioxidants ergothioneine and glutathione. Food Chem. 2017;233:429-433
• Geissler T, Brandt W, Porzel A, Novak C, Strach A, et al. Unveiling the chemical composition and biofunctionality of Hericium spp. fungi: a comprehensive overview. Int J Mol Sci. 2024;25(11):5949
• Ginns J. Hericium in North America: cultural characteristics and mating behaviour with notes on H. erinaceus and H. americanum. Can J Bot. 1985;63(7):1551-1563
• He X, Wang X, Fang J, Chang Y, Ning N, Guo H, et al. Structures, biological activities, and industrial applications of the polysaccharides from Hericium erinaceus (Lion’s Mane) mushroom: a review. Int J Biol Macromol. 2017;97:228-237

Connections

• Hericium erinaceus (Lion’s Mane): Lion’s Mane is the most closely related and extensively studied Hericium species. Both share hericenones, erinacines, and beta-glucans as primary bioactives. H. erinaceus has multiple published clinical trials supporting neurocognitive benefits, making it the evidence leader in the genus. H. americanum may serve as a North American wild-harvested alternative.
• Hericium coralloides (Coral Tooth): Coral Tooth is another Hericium species with more extensively branched morphology. It shares the genus-level bioactive compound classes and may have similar neurocognitive potential.
• Reishi (Ganoderma lucidum): Reishi is commonly paired with Hericium species in integrative protocols combining immune modulation (Reishi) with neurocognitive support (Hericium).
• Cordyceps (Cordyceps spp.): Cordyceps is another commonly paired medicinal mushroom in integrative brain health and energy protocols, providing complementary mitochondrial support alongside Hericium’s NGF-stimulating activity.